Endocrine Abstracts

Introduction: 177Lu-Oxodotreotide(PRRT-Lu) has the approval by EMA and FDA since 2017 for the treatment of patients with gastro-entero-pancreatic neuroendocrine tumors(GEP-NET). However, in daily clinical practice it has also been used in other NET tumors such as paragangliomas, lung NET, medullary thyroid cancer, and others. The aim of this study is to describe the characteristics and follow-up of patients treated with PRRT-Lu in a third level hospital in Spain fro...

Introduction: Pheochromocytomas(PCC) and paragangliomas(PGGLs) are rare neuroendocrine tumors. Management is very complex, this is why physicians involved in the management of these patients need to take into account not only clinical aspects but also genetics of these tumors. We present a group of patients diagnosed of metastatic PGG or PCC, their characteristics and long term follow-up.Methods and design: Descriptive and unicentric study that includes ...

Introduction: Paragangliomas and pheochromocytomas (PGGs) are infrequent tumors of the autonomic nervous system that represent a diagnostic and therapeutic challenge. Management and follow-up of PGGs requires specialized knowledge and solid experience, which, given the rarity of these diseases, is available only in highly specialized centers. University Hospital La Fe (Spain) was designated a reference unit on Neuroendocrine Tumors by local sanitary authorities in 2018. The ai...